Buprenorphine and Conivaptan: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Conivaptan
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Let's talk about taking buprenorphine (your pain or opioid-treatment medicine) together with conivaptan (a hospital medicine used for low sodium). Conivaptan slows down a liver enzyme that normally breaks buprenorphine down. When that happens, more buprenorphine stays in your body, so its effects can get stronger and last longer.
The main thing to watch for is too much sedation (feeling very drowsy or hard to wake) and slowed breathing. This is a known and real interaction, but it is very manageable. Your care team can adjust your buprenorphine dose and keep a closer eye on you while you use both, so please don't change anything on your own.
Effect: Conivaptan (CYP3A4 inhibitor) reduces CYP3A4-mediated metabolism of buprenorphine, increasing buprenorphine plasma concentrations and exposure. Direction is increased opioid effect, raising the risk of sedation and respiratory depression.
- Mechanism: CYP3A4 inhibition (buprenorphine is a CYP3A4 substrate, not a prodrug requiring activation).
- Severity/evidence: Major; probable. Onset unspecified.
- Management: If conivaptan is required, consider reducing buprenorphine dose until stable effects are achieved and monitor frequently for sedation/respiratory depression. On conivaptan discontinuation, anticipate falling buprenorphine levels and monitor for withdrawal; a dose increase may be needed. For subQ depot formulations, favor formulations allowing precise titration and monitor for over-medication.
What happens
Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events
Interaction Deep Dive
Because plasma buprenorphine concentrations rise when buprenorphine is combined with a CYP3A4 inhibitor, extended opioid effects such as respiratory depression can result. Should a CYP3A4 inhibitor be required for a patient already on buprenorphine, it is advisable to lower the buprenorphine dose until stable drug effects are reached, while frequently checking for sedation and respiratory depression. Conversely, when a CYP3A4 inhibitor is being stopped in a patient on buprenorphine therapy, a buprenorphine dose increase should be considered until stable drug effects are attained, with monitoring for signs of opioid withdrawal2. When dose adjustment is not possible once the CYP3A4 inhibitor has been removed, the patient should be switched back to a buprenorphine formulation that allows finer dose control. For patients being changed over from transmucosal buprenorphine given together with CYP3A4 inhibitors, verify that the plasma buprenorphine level delivered by subQ buprenorphine is sufficient. For patients already receiving subQ buprenorphine who then need a CYP3A4 inhibitor, watch for signs and symptoms of over-medication. Should buprenorphine toxicity or overdose signs and symptoms appear while the concomitant medication cannot be lowered or stopped, decrease the buprenorphine dose. If the available doses cannot deliver the intended dose, stop treatment and manage the patient with a buprenorphine formulation that allows more precise dose adjustments 1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both medications exactly as prescribed unless your care team tells you otherwise. This interaction is well recognized and manageable.
- Your team may lower your buprenorphine dose while you are on conivaptan and watch you more closely for heavy drowsiness or slowed breathing.
- When conivaptan is stopped, they may raise your buprenorphine dose back and watch for signs of opioid withdrawal.
- If you are on a long-acting injectable form that is hard to fine-tune, your team may switch you to a form that allows more precise dose adjustments.
- Get help right away for extreme sleepiness, confusion, or trouble breathing.
Ask your pharmacist or prescriber before changing anything.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) Studies have not examined how concurrently administered CYP3A4 inhibitors affect buprenorphine exposure in individuals receiving subQ buprenorphine; nevertheless, these interactions have been demonstrated in investigations involving transmucosal buprenorphine. Buprenorphine's effects may vary according to the route by which it is administered 1.
Common questions
Can I take Buprenorphine and Conivaptan together?
Conivaptan can raise buprenorphine levels and increase the risk of heavy sedation and slowed breathing; your care team can manage this by adjusting your buprenorphine dose and monitoring you more closely, so do not change either medicine on your own. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Conivaptan interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Conivaptan interaction managed?
Keep taking both medications exactly as prescribed unless your care team tells you otherwise. This interaction is well recognized and manageable. Your team may lower your buprenorphine dose while you are on conivaptan and watch you more closely for heavy drowsiness or slowed breathing. When conivaptan is stopped, they may raise your buprenorphine dose back and watch for signs of opioid withdrawal.… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Buprenorphine or Conivaptan need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Buprenorphine
Keep reading about Conivaptan
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist